MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
152.50
+3.13
+2.10%
After Hours: 152.25 -0.25 -0.16% 19:56 02/06 EST
OPEN
149.69
PREV CLOSE
149.37
HIGH
153.13
LOW
148.71
VOLUME
8.51M
TURNOVER
--
52 WEEK HIGH
153.13
52 WEEK LOW
91.47
MARKET CAP
189.20B
P/E (TTM)
23.70
1D
5D
1M
3M
1Y
5Y
1D
Gilead wins favorable U.S. label update for Yescarta
Seeking Alpha · 10h ago
Invesco QQQ Trust ETF (QQQ) Daily Update, 2/6/2026
TipRanks · 11h ago
Kite announces FDA approval for updated Yescarta label
TipRanks · 12h ago
FDA Approves Label Update For Gilead's Kite's Yescarta
Benzinga · 12h ago
FDA Removes Limitations on Yescarta for Central Nervous System Lymphoma
Reuters · 12h ago
FDA hebt Einschränkung für Yescarta bei ZNS-Lymphom nach positiver Sicherheitsstudie auf
Reuters · 12h ago
FDA APPROVES LABEL UPDATE FOR KITE’S YESCARTA® FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Reuters · 12h ago
Gilead Sciences (GILD) Valuation Check After Oncology And HIV Therapy Momentum
Simply Wall St · 15h ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.